USP8 and neoplasm: Furthermore, in vitro, the USP8 inhibitor-αPD-L1 combination therapy promoted activated T cell-mediated tumor cell killing significantly compared with the USP8 inhibitor treatment group or the αPD-L1 therapy group (Fig. S9h, i).